Back

Population-based cervical screening with Human Papillomavirus self-sampling at home and incidence of cervical cancer

andersson, h.; Dillner, J.

2026-01-16 epidemiology
10.64898/2026.01.15.26344201 medRxiv
Show abstract

ObjectiveTo describe the Swedish 2020 switch to primary cervical screening using Human Papillomavirus (HPV) self-sampling at home and compare with cervical cancer incidence trends. MethodsStatistics on HPV self-sampling and cervical cancer incidence were obtained from comprehensive nationwide registries. ResultsHPV self-sampling was recommended in 2017 for non-attending women and was in 2020 recommended as a primary screening for all women aged 23-70 years of age. During 2016-2020 there were <20,000 annual self-samples taken, but since 2021 >200,000 self-samples are taken annually (about half of all screening tests). During 2015 to 2020 the cervical cancer incidence was stable, between 11 and 12 per 100,000 women. From 2021 and onwards the incidence is declining and was 7,7/100,000 in 2024. The decline is stronger among women younger than 30 (-60%) but is strong in all ages (-27%). ConclusionsA rapid introduction of primary HPV self-sampling at home in 2020-2021 was followed by a rapid decline in invasive cervical cancer incidence.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.